Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double‐blind, parallel‐controlled trial

兰索拉唑 医学 胃肠病学 质子抑制剂泵 随机对照试验 内科学 双盲 不利影响 入射(几何) 安慰剂 奥美拉唑 光学 物理 病理 替代医学
作者
Niandi Tan,Xiaowei Liu,Chengxia Liu,Shengbao Li,Honghui Chen,Xing Li,Hao Wu,Aijun Liao,Yan‐bo Zhen,Peng‐zhen Shen,Lijuan Huo,H Liu,Shi Rui-hua,Bingqiang Zhang,Zhenyu Zhang,Jianning Wang,Qiang Zhan,Hong Deng,Xu Shu,Biguang Tuo,Qizhi Wang,Shiyu Du,Lingzhi Qi,Guoxin Zhang,Qiong Peng,Bangmao Wang,Bin Ye,Minhu Chen,Ying Xiao
出处
期刊:Journal of Gastroenterology and Hepatology [Wiley]
卷期号:37 (11): 2060-2066 被引量:6
标识
DOI:10.1111/jgh.16000
摘要

Abstract Background and Aim Considering the limitation of varying acid suppression of proton pump inhibitors, this study was aimed to assess the efficacy, safety, and dose–effect relationship of keverprazan, a novel potassium‐competitive acid blocker, in the treatment of duodenal ulcer (DU) compared with lansoprazole. Methods A randomized, double‐blind, double‐dummy, multicenter, low‐dose, high‐dose, and positive‐drug parallel‐controlled study was conducted to verify the non‐inferiority of keverprazan (20 or 30 mg) to lansoprazole of 30 mg once daily for 4 to 6 weeks and dose–effect relationship of keverprazan in the treatment of patients with active DU confirmed by endoscopy. Results Of the 180 subjects randomized, including 55 cases in the keverprazan_20 mg group, 61 cases in the keverprazan_30 mg group, and 64 cases in the lansoprazole_30 mg group, 168 subjects (93.33%) completed the study. The proportions of healed DU subjects in the keverprazan_20 mg, keverprazan_30 mg, and lansoprazole_30 mg groups were respectively 87.27%, 90.16%, and 79.69% at week 4 ( P = 0.4595) and were respectively 96.36%, 98.36%, and 92.19% at week 6 ( P = 0.2577). The incidence of adverse events in the keverprazan_20 mg group was lower than that in the lansoprazole_30 mg ( P = 0.0285) and keverprazan_30 mg groups ( P = 0.0398). Conclusions Keverprazan was effective and non‐inferior to lansoprazole in healing DU. Based on the comparable efficacy and safety data, keverprazan of 20 mg once daily is recommended for the follow‐up study of acid‐related disorders. (Trial registration number: ChiCTR2100043455.)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
FashionBoy应助科研通管家采纳,获得10
2秒前
2秒前
GGBOND2024应助科研通管家采纳,获得10
2秒前
FashionBoy应助科研通管家采纳,获得10
2秒前
tanuki应助科研通管家采纳,获得10
3秒前
chen应助科研通管家采纳,获得50
3秒前
所所应助科研通管家采纳,获得10
3秒前
科研通AI2S应助科研通管家采纳,获得10
3秒前
3秒前
3秒前
4秒前
wanci应助魏ye采纳,获得10
4秒前
5秒前
蟹老板发布了新的文献求助10
5秒前
吃不饱星球球长应助TQ05588采纳,获得10
5秒前
情怀应助单薄的白翠采纳,获得10
6秒前
6秒前
852应助suiyi采纳,获得10
6秒前
张龙雨发布了新的文献求助10
6秒前
坚定的平松完成签到,获得积分10
7秒前
沉静道罡完成签到,获得积分10
8秒前
慕文颜雨完成签到,获得积分10
8秒前
123456完成签到,获得积分10
9秒前
傅傅发布了新的文献求助10
9秒前
欢喜的慕青完成签到,获得积分10
10秒前
10秒前
11秒前
lhy完成签到,获得积分10
12秒前
柯仇天发布了新的文献求助10
12秒前
科研小白发布了新的文献求助10
12秒前
13秒前
14秒前
万能图书馆应助vincen91采纳,获得10
14秒前
14秒前
舒心一兰发布了新的文献求助10
16秒前
kento应助陶醉觅夏采纳,获得200
16秒前
沉静的香烟完成签到,获得积分10
17秒前
17秒前
研友_VZG7GZ应助柊璃采纳,获得10
17秒前
高分求助中
Sustainability in ’Tides Chemistry 2000
Sustainability in ’Tides Chemistry 1500
The ACS Guide to Scholarly Communication 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
Photosynthesis III 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3071500
求助须知:如何正确求助?哪些是违规求助? 2725527
关于积分的说明 7489890
捐赠科研通 2372698
什么是DOI,文献DOI怎么找? 1258220
科研通“疑难数据库(出版商)”最低求助积分说明 610233
版权声明 596916